论文部分内容阅读
目的:观察急性心肌梗死(AMI)患者冠状动脉介入治疗(PCI)后长期服用曲美他嗪的临床疗效和不良反应。方法:初发AMI患者90例,PCI后随机分为3组:A组(30例)作为对照;B组(30例)PCI后口服曲美他嗪治疗6个月;C组(30例)PCI后口服曲美他嗪治疗12个月。各组有关冠心病2级预防用药均相同。观察各组患者肾功能、24h尿蛋白定量、超声心动图变化。结果:与A组相比,B组和C组肾功能未见恶化,24h尿蛋白定量无增加,心功能恢复较好(均P<0.05或P<0.01)。B组和C组比较各指标均差异无统计学意义(均P>0.05)。结论:AMI患者PCI后长期服用曲美他嗪安全有效,心功能改善明显。
Objective: To observe the long-term clinical efficacy and side effects of trimetazidine after percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI). Methods: Ninety patients with AMI were randomly divided into three groups: group A (30 cases) as control group, group B (30 cases) PCI after triamcinolone acetonide treatment for 6 months, group C (n = 30) After oral trimetazidine treatment of PCI for 12 months. Coronary heart disease in each group 2 prevention medication are the same. Renal function, 24h urinary protein quantitation and echocardiography were observed in each group. Results: Compared with group A, the renal function of group B and group C did not deteriorate, and the quantity of urinary protein increased 24h without any increase (P <0.05 or P <0.01). There was no significant difference in each index between group B and group C (all P> 0.05). Conclusion: The long-term use of trimetazidine in patients with AMI after PCI is safe and effective, with significant improvement of cardiac function.